A Study to Assess the Efficacy and Safety of IMAB362 in Combination With Nab-Paclitaxel and Gemcitabine (Nab-P + GEM) as First Line Treatment in Subjects With Claudin 18.2 (CLDN18.2) Positive, Metastatic Pancreatic Adenocarcinoma

~27 mi. (Quintaine, France, +84 more cities)

Site FR33003

CLDN18 Expression

Pancreatic Adenocarcinoma

gemcitabine, +2 more drugs

chemotherapy, +1 more type

Study of Pembrolizumab (MK-3475) Versus Placebo in Combination With Neoadjuvant Chemotherapy & Adjuvant Endocrine Therapy in the Treatment of Early-Stage Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative (ER+/HER2-) Breast Cancer (MK-3475-756/KEYNOTE-756)

~57 mi. (Dijon, France, +207 more cities)

Centre Georges Francois Leclerc ( Site 0920)

ER Positive, +1 more biomarker

Breast Invasive Ductal Carcinoma

cyclophosphamide, +6 more drugs

chemotherapy, +3 more types

Perioperative Pembrolizumab (MK-3475) Plus Cystectomy or Perioperative Pembrolizumab Plus Enfortumab Vedotin Plus Cystectomy Versus Cystectomy Alone in Cisplatin-ineligible Participants With Muscle-invasive Bladder Cancer (MK-3475-905/KEYNOTE-905/EV-303)

~57 mi. (Dijon, France, +163 more cities)

Centre Georges Francois Leclerc ( Site 0488)

Bladder Urothelial Carcinoma

cystectomy, +2 more drugs

chemotherapy, +3 more types

Efficacy and Safety of Lenvatinib (E7080/MK-7902) Plus Pembrolizumab (MK-3475) Plus Chemotherapy in Participants With Advanced/Metastatic Gastroesophageal Adenocarcinoma (MK-7902-015/E7080-G000-321/LEAP-015)

~57 mi. (Dijon, France, +131 more cities)

Centre Georges Francois Leclerc ( Site 1106)

HER2 Negative

Adenocarcinoma of the Gastroesophageal Junction, +2 more conditions

CAPOX regimen, +3 more drugs

chemotherapy, +2 more types

A Phase 3 Efficacy, Safety and Tolerability Study of Zolbetuximab (Experimental Drug) Plus mFOLFOX6 Chemotherapy Compared to Placebo Plus mFOLFOX6 as Treatment for Gastric and Gastroesophageal Junction (GEJ) Cancer

~57 mi. (Dijon, France, +202 more cities)

Site FR33009

CLDN18 Expression, +1 more biomarker

Adenocarcinoma of the Gastroesophageal Junction, +1 more condition

modified FOLFOX6 regimen, +1 more drug

chemotherapy, +1 more type

Study of Pembrolizumab (MK-3475) Versus Placebo in Participants With Esophageal Carcinoma Who Are Receiving Chemotherapy and Radiation Therapy (MK-3475-975/KEYNOTE-975)

~57 mi. (Dijon, France, +126 more cities)

Centre Georges Francois Leclerc ( Site 0223)

Adenocarcinoma of the Gastroesophageal Junction, +1 more condition

FOLFOX regimen, +3 more drugs

chemotherapy, +2 more types

Efficacy and Safety of Olaparib (MK-7339) in Participants With Previously Treated, Homologous Recombination Repair Mutation (HRRm) or Homologous Recombination Deficiency (HRD) Positive Advanced Cancer (MK-7339-002 / LYNK-002)

~57 mi. (Dijon, France, +105 more cities)

Centre Georges Francois Leclerc ( Site 0608)

ATM Loss, +62 more biomarkers

Breast Carcinoma, +2 more conditions

olaparib

targeted therapy

A Study of Selpercatinib (LY3527723) in Participants With RET-Mutant Medullary Thyroid Cancer

~57 mi. (Dijon, France, +143 more cities)

Centre Georges François Leclerc

RET Mutation

Thyroid Gland Medullary Carcinoma

selpercatinib

targeted therapy

MK-7684A With or Without Other Anticancer Therapies in Participants With Selected Solid Tumors (MK-7684A-005)

~57 mi. (Dijon, France, +32 more cities)

Centre Georges François Leclerc ( Site 1155)

ER Negative, +2 more biomarkers

Adenocarcinoma of the Gastroesophageal Junction, +12 more conditions

cisplatin, +4 more drugs

chemotherapy, +2 more types

Study of Adjuvant Cemiplimab Versus Placebo After Surgery and Radiation Therapy in Patients With High Risk Cutaneous Squamous Cell Carcinoma

~57 mi. (Dijon, France, +118 more cities)

Regeneron Research Site

Skin Squamous Cell Carcinoma

cemiplimab

immunotherapy

Futibatinib in Patients With Specific FGFR Aberrations

~57 mi. (Dijon, France, +53 more cities)

Centre Georges François Leclerc

FGFR1 Fusion, +4 more biomarkers

Adenocarcinoma of the Gastroesophageal Junction, +4 more conditions

futibatinib

targeted therapy

Efficacy, Safety, and Tolerability of V937 Administered Intravenously or Intratumorally With Pembrolizumab (MK-3475) Versus Pembrolizumab Alone in Participants With Advanced/Metastatic Melanoma (V937-011)

~57 mi. (Dijon, France, +25 more cities)

Centre Georges Francois Leclerc ( Site 2025)

Melanoma

coxsackievirus A21, +1 more drug

immunotherapy